Stocks Cut Losses on Hormuz Report, Oil Holds Gains | Closing Bell
Comprehensive cross-platform coverage of the U.S. market close on Bloomberg Television, Bloomberg Radio, and YouTube with Scarlet Fu, Katie Greifeld, Carol Massar and Tim Stenovec.
Applications for US unemployment benefits fell last week to just shy of a two-year low as Initial claims decreased by 9,000 to 202,000. Meanwhile, the US trade deficit widened in February by less than forecast on an increase in both imports and exports. Michael McKee reports on Bloomberg Television.
Lindsay (NYSE:LNN) reported a sharp decline in second-quarter profitability as a contraction in both its agricultural and infrastructure segments weighed on the top line, leading to a more than 50% drop in net earnings.

Acuity Brands (NYSE:AYI) reported a surge in second-quarter profitability and rewarded shareholders with an 18% dividend hike, as the company’s expansion into intelligent infrastructure compensated for a leaner performance in its core lighting segment.

Tesla (NASDAQ:TSLA) reported first-quarter delivery numbers that fell short of Wall Street expectations, raising fresh concerns about a widening gap between the electric vehicle maker's manufacturing pace and global consumer appetite.

ECARX Holdings (NASDAQ:ECX) achieved a historic financial turning point in the final months of 2025, reporting its first-ever quarterly net income as a public company alongside a surge in shipments for its flagship automotive computing platforms.
Merck (NYSE:MRK) has secured a landmark regulatory approval in the European Union for its blockbuster immunotherapy Keytruda, marking the region’s first PD-1 inhibitor authorized to treat a particularly aggressive form of ovarian cancer.
AstraZeneca (NASDAQ:AZN) announced positive high-level results from its EMERALD-3 Phase III trial, demonstrating that a novel combination of immunotherapies and targeted treatment significantly improved outcomes for patients with the most common form of liver cancer.
AirSculpt Technologies (NASDAQ:AIRS), a national provider of body contouring procedures, reported its fourth-quarter and full-year fiscal 2025 financial results.
Cheche Group (NASDAQ:CCG) reported its unaudited financial results for the second half and full year ended December 31, 2025, on Thursday, April 2, 2026.
Immunovant (NASDAQ:IMVT) announced topline results from two Phase 3 clinical studies evaluating batoclimab in patients with active, moderate-to-severe thyroid eye disease (TED) on Thursday, April 2, 2026.